These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32129745)

  • 1. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
    Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
    Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the adenosine pathway for cancer immunotherapy.
    Hammami A; Allard D; Allard B; Stagg J
    Semin Immunol; 2019 Apr; 42():101304. PubMed ID: 31604539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory role of CD39 and CD73 in tumor immunity.
    Kaplinsky N; Williams K; Watkins D; Adams M; Stanbery L; Nemunaitis J
    Future Oncol; 2024; 20(19):1367-1380. PubMed ID: 38652041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
    Kumar M; Lowery R; Kumar V
    SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
    Allard B; Longhi MS; Robson SC; Stagg J
    Immunol Rev; 2017 Mar; 276(1):121-144. PubMed ID: 28258700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cancer-derived adenosine: new therapeutic approaches.
    Young A; Mittal D; Stagg J; Smyth MJ
    Cancer Discov; 2014 Aug; 4(8):879-88. PubMed ID: 25035124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD73 and adenosine generation in the creation of regulatory microenvironments.
    Regateiro FS; Cobbold SP; Waldmann H
    Clin Exp Immunol; 2013 Jan; 171(1):1-7. PubMed ID: 23199317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting adenosine and regulatory T cells in cancer immunotherapy.
    Churov A; Zhulai G
    Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.
    Sauer AV; Brigida I; Carriglio N; Hernandez RJ; Scaramuzza S; Clavenna D; Sanvito F; Poliani PL; Gagliani N; Carlucci F; Tabucchi A; Roncarolo MG; Traggiai E; Villa A; Aiuti A
    Blood; 2012 Feb; 119(6):1428-39. PubMed ID: 22184407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reduced frequency of CD39
    Dong K; Wang Y; Yao Y; Yu W; Xu Z; Chen Y; Geng L; Wang S
    Int Immunopharmacol; 2024 Oct; 140():112743. PubMed ID: 39094356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the CD39-CD73-adenosine pathway in liver disease.
    Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
    J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function.
    Lee JJ; Jeong HJ; Kim MK; Wee WR; Lee WW; Kim SU; Sung C; Yang YH
    Purinergic Signal; 2014; 10(2):357-65. PubMed ID: 24043462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of CD73 as a target for cancer immunotherapy.
    Jadidi-Niaragh F
    Immunotherapy; 2019 Nov; 11(16):1353-1355. PubMed ID: 31578906
    [No Abstract]   [Full Text] [Related]  

  • 16. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
    Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
    Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential role of the CD39-CD73 ATP-adenosine pathway in platelet mediated dissemination of circulating tumour cells.
    Ward MP; O'Toole SA; O'Leary JJ
    Br J Cancer; 2024 Sep; 131(5):781-782. PubMed ID: 39128932
    [No Abstract]   [Full Text] [Related]  

  • 19. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the CD73-adenosine axis in immuno-oncology.
    Allard D; Chrobak P; Allard B; Messaoudi N; Stagg J
    Immunol Lett; 2019 Jan; 205():31-39. PubMed ID: 29758241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.